The Anterior Chamber Injection of Moxifloxacin Injection to Prevent Endophthalmitis after Cataract Surgery: A Meta-analysis

Table 1

Characteristics of the included studies (n = 8).

Study	Site	Designs	The number of the eyes		Age		Treatment options	Follow-up	Outcomes
			Moxifloxacin	Control	Moxifloxacin	Control
Melega et al. [11]	Brazil	RCT	1818	1822	68.50 ± 9.72	68.49 ± 9.63	0.5% moxifloxacin	6 w	ECD, IOP, CCT, and the incidence of endophthalmitis
Lane et al. [17]	USA	RCT	26	31	74 ± 9.3	74 ± 9.3	0.5% moxifloxacin	3 m	UCVA, IOP, ECD, and CCT
Cetinkaya et al. [12]	Turkey	Case-control study	33	32	64.81 ± 11.61	65.43 ± 11.10	0.5% moxifloxacin	1 y	BCVA, IOP, and corneal edema
Rudnisky et al. [13]	Canada	Case-control study	33039	42256	NA	NA	0.5% moxifloxacin	6 w	The incidence of endophthalmitis
Virgilio et al. [18]	Colombia	Cohort study	1618	1056	67.2 ± 11.3	67.2 ± 11.3	0.5% moxifloxacin	2 w	The incidence of endophthalmitis
Matsuura et al. [15]	Japan	Cohort study	69	69	71.9 ± 7.5	71.9 ± 7.5	0.5% moxifloxacin	3 m	UCVA, BCVA, IOP, ECD, and CCT
Matsuura et al., [16]	Japan	Cohort study	18797	15958	NA	NA	0.1%, 0.3%, and 0.5% moxifloxacin	1 m	The incidence of endophthalmitis
Vieira et al. [14]	Brazil	Cohort study	3680	3515	67.7 ± 9.03	68.1 ± 8.92	0.5% moxifloxacin	1 m	The incidence of endophthalmitis

Abbreviations: BCVA, best corrected visual acuity; UCVA, uncorrected visual acuity; IOP, intraocular pressure; ECD, corneal endothelial cell density; CCT, central corneal thickness; NA, data not available; y, year; m, month; w, week.